MENURogel Cancer Center at the American Society of Hematology Annual Conference
Researchers from the University of Michigan Rogel Cancer Center will attend the American Society of Hematology (ASH) Annual Conference Annual Meeting from Saturday, December 1 through Tuesday, December 4. Many of them plan to participate in poster sessions and oral presentations. Below is a schedule of who is presenting, when, where and on what topic. Unless otherwise noted, all the presentations take place in the San Diego Convention Center.
Monday, December 3, 2018
2:45 - 4:15pm
Challice L. Bonifant, M.D., Ph.D. : MODERATOR Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Pre-clinical T and NK Cell Immunotherapies
Oral Abstracts. Room 8
Jordan K. Schaefer, M.D. : MODERATOR Health Services Research—Non-Malignant Conditions: Bone Marrow Transplantation and Benign Hematology
Room 9
4pm
Eric Perkey, B.S.: Donor T Cells Require Notch Signals but Not Alloantigen Presentation from Specialized Secondary Lymphoid Organ Fibroblasts to Drive Graft-Versus-Host Disease
Grand Hall C (Manchester Grand Hyatt San Diego)
4:30pm
Pavan Reddy, M.D., and Stephanie Kim, B.S. : Targeting Sec23b in COPII Vesicles Regulates T Cell Immunity
Oral Abstract, Room 8
6 - 8pm
Dale Bixby, M.D., Ph.D. and Lauren E. Merz, B.A.: Lenalidomide Plus Hypomethylating Agent for Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities -AML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, Mecom
Poster Abstract, Hall GH
Malathi Kandarpa, Ph.D., Kristen Pettit, M.D. and Moshe Talpaz, M.D.: Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity
Poster Abstract, Hall GH
Thomas F. Michniacki, M.D.: Neutropenia Is an Under-Recognized Finding in Pediatric Primary Immunodeficiency Diseases: An Analysis of the United States Immunodeficiency Network Registry
Poster Session, Hall GH
Dan Peltier, M.D.: RNA-Seq of Human T Cells after BMT Identifies Linc00402 As a Novel Regulator of Human T Cell Alloimmunity
Poster Session, Hall GH
Tycel J. Phillips, M.D.: Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Poster Session, Hall GH
John Reneau, M.D.: Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders
Poster Abstract, Hall GH